Clinical outcomes of CyberKnife stereotactic body radiotherapy for peripheral stage I non-small cell lung cancer

被引:0
作者
Ze-Tian Shen
Xin-Hu Wu
Bing Li
Xi-Xu Zhu
机构
[1] Medical School of Nanjing University,Department of Radiation Oncology, Jinling Hospital
来源
Medical Oncology | 2015年 / 32卷
关键词
NSCLC; CyberKnife; SBRT; Clinical outcomes;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of this study was to evaluate the clinical outcome of CyberKnife stereotactic body radiotherapy (SBRT) for patients with stage I non-small cell lung cancer (NSCLC). Fifty patients with peripheral stage I NSCLC who refused surgery or were medically inoperable were treated with 48–60 Gy (median dose: 57 Gy) in three divided doses. Histopathology was available in 86 % of patients. Thirty patients had a T1 tumor, and 20 patients had T2 tumors. More than 95 % of the target volume was covered by the 72 % isodose surface. Fiducials were implanted in or near the tumors in all patients to track tumor movement and breathing patterns. The median follow-up time was 35 months (3–45 months). Based on computed tomography scans, 40 patients achieved complete remission, six patients achieved partial remission, two patients exhibited stable disease, and two patients had progressive disease. The local control rate (CR + PR) was 92 %, and the 2-year disease control rate (CR + PR + SD) was 96 %. Overall survival for the whole group was 86 % at 1 year and 74 % at 2 years. Grade III toxicity occurred in two patients (4 %) after marker placement. Treatment-related late grade III toxicity occurred in five patients (10 %). Toxicities greater than grade III were not observed. CyberKnife SBRT achieves a high rate of local control and long-term curative effect with acceptable toxicity for patients with inoperable stage I NSCLC. However, long-term follow-up is necessary to evaluate survival and late toxicity.
引用
收藏
相关论文
共 106 条
[1]  
Kaskowitz L(1993)Radiation therapy alone for stage I non-small cell lung cancer Int J Radiat Oncol Biol Phys 27 517-523
[2]  
Graham MV(1998)Radiotherapy alone for medically inoperable stage I non-small cell lung cancer: the Duke experience Int J Radiat Oncol Biol Phys 40 149-154
[3]  
Emami B(1995)Randomised trial of lobectomy versus limited resection for T1N0 non-small cell lung cancer patients. Lung cancer study group Ann Thorac Surg 60 615-623
[4]  
Halverson KJ(1988)Prognosis and survival in resected lung carcinoma based on the new international staging system J Thorac Cardiovasc Surg 96 440-447
[5]  
Rush C(2008)Feasibility and efficacy of CyberKnife radiotherapy for lung cancer: early results Cancer Radiother 12 793-799
[6]  
Sibley GS(2007)CyberKnife radiosurgery for stage I lung cancer: results at 36 months Clin Lung Cancer 8 488-492
[7]  
Jamieson TA(2005)Robotic whole body stereotactic radiosurgery: clinical advantages of the Cyberknife integrated system Int J Med Robot 1 29-39
[8]  
Marks LB(2004)Measurements of the relative output factors for CyberKnife collimators Neurosurgery 54 157-161
[9]  
Anscher MS(2009)New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
[10]  
Prosnitz LR(2007)Accuracy of tumor motion compensation algorithm from a robotic respiratory tracking system: a simulation study Med Phys 34 2774-2784